Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 14/20 | 0.59 |
| ▸ | GPBAR1 | Q8TDU6 | 4/20 | 0.53 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.53 |
| ▸ | RORC | P51449 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20957462 | 1.00 | NR1H4 (0.59) | NR1H4GPBAR1PRKCDRORC | |
| SCHEMBL9105004 | 1.00 | NR1H4 (0.59) | NR1H4GPBAR1PRKCDRORC | |
| SCHEMBL20993903 | 0.96 | NR1H4 (0.57) | NR1H4GPBAR1PRKCDRORC | |
| SCHEMBL20957456 | 0.96 | NR1H4 (0.57) | NR1H4GPBAR1PRKCDRORC | |
| SCHEMBL15917601 | 0.94 | NR1H4 (0.53) | NR1H4GPBAR1RORC | |
| SCHEMBL9107955 | 0.93 | NR1H4 (0.61) | NR1H4GPBAR1RORC | |
| SCHEMBL20957457 | 0.93 | NR1H4 (0.61) | NR1H4GPBAR1RORC | |
| SCHEMBL20993922 | 0.92 | NR1H4 (0.50) | NR1H4GPBAR1PRKCD | |
| SCHEMBL9107213 | 0.92 | NR1H4 (0.65) | NR1H4GPBAR1PRKCD | |
| SCHEMBL9106823 | 0.92 | NR1H4 (0.65) | NR1H4GPBAR1PRKCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190135857-A1 | TRITERPENOID INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BRISTOL-MYERS SQUIBB COMPANY | 2019-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190135857-A1 | TRITERPENOID INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | CYP51A1, LSS, CCNI | NR1H4 1283/4885GPBAR1 3425/4885PRKCD 3066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.